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Racemic baclofen [(±)-baclofen] has repeatedly been reported to suppress several 
 alcohol-motivated behaviors, including alcohol drinking and alcohol self-administration,  
in rats and mice. Recent data suggested that baclofen may have bidirectional, ste-
reospecific effects, with the more active enantiomer, R(+)-baclofen, suppressing alco-
hol intake and the less active enantiomer, S(−)-baclofen, stimulating alcohol intake in 
mice. The present study was designed to investigate whether this enantioselectivity of 
baclofen effects may also extend to the reinforcing properties of alcohol in rats. To this 
end, selectively bred Sardinian alcohol-preferring (sP) rats were initially trained to lever 
respond on a fixed ratio 4 (FR4) schedule of reinforcement for alcohol (15%, v/v) in 
daily 30-min sessions. Once responding had stabilized, rats were tested with vehicle, 
(±)-baclofen (3 mg/kg), R(+)-baclofen (0.75, 1.5, and 3 mg/kg), and S(−)-baclofen (6, 12, 
and 24  mg/kg) under the FR4 schedule of reinforcement. Treatment with 3  mg/kg 
(±)-baclofen reduced the number of lever responses for alcohol and estimated amount 
of self-administered alcohol by approximately 60% in comparison to vehicle treatment. 
R(+)-baclofen was approximately twice as active as (±)-baclofen: treatment with 1.5 mg/
kg R(+)-baclofen decreased both variables to an extent similar to that of the decreasing 
effect of 3 mg/kg (±)-baclofen. Conversely, treatment with all doses of S(−)-baclofen 
failed to affect alcohol self administration. These results (a) confirm that non-sedative 
doses of (±)-baclofen effectively suppressed the reinforcing properties of alcohol in sP 
rats and (b) apparently do not extend to operant alcohol self-administration in sP rats the 
capability of S(−)-baclofen to stimulate alcohol drinking in mice.
Keywords: (±)-baclofen, r(+)-baclofen, s(−)-baclofen, gaBaB receptor, operant oral alcohol self-administration, 
sardinian alcohol-preferring rats
inTrODUcTiOn
Over the last 15 years, multiple lines of experimental evidence have demonstrated, with relatively 
few exceptions, that treatment with non-sedative doses of the prototypic GABAB receptor agonist, 
baclofen, suppressed several alcohol-related behaviors – including alcohol drinking, operant alcohol 
self-administration, reinstatement of alcohol-seeking behavior, and alcohol-induced conditioned 
place preference  –  in rats, mice, and monkeys (1–3). These data have prompted several clinical 
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investigations, the majority of which have extended to human 
alcoholics the results previously collected in laboratory animals: 
treatment with baclofen has often been associated with suppres-
sion of alcohol consumption, craving for alcohol, and severity of 
alcohol withdrawal syndrome (2, 4–6), making baclofen a novel, 
promising therapeutic option for alcohol use disorder, with an 
already widespread use in France [e.g., Ref. (7–13)].
At preclinical level, a recent and important discovery in the 
alcohol and baclofen research field has been the observation 
that the suppressing effect of baclofen on alcohol intake may 
be enantiomer dependent. Indeed, two recent studies demon-
strated that acute treatment with the two baclofen enantiomers, 
R(+)-baclofen, and S(−)-baclofen, resulted in clearly opposite 
effects on alcohol drinking in mice: equal doses of the more 
active enantiomer, R(+)-baclofen, suppressed alcohol intake 
and of the less active enantiomer, S(−)-baclofen, stimulated 
alcohol intake in (a) C57BL/6J mice exposed to an experimental 
procedure inducing binge-like drinking and (b) selectively bred 
high alcohol preferring (HAP) mice exposed to chronic alcohol 
drinking (14, 15); this differential effect was observed after both 
parenteral administration (15) and infusion into the shell of 
the nucleus accumbens (14) of the two baclofen enantiomers. 
Notably, all previous studies investigating the effect of baclofen 
on alcohol-related behaviors have been conducted using race-
mic baclofen [e.g., Ref. (16–30)]; to the best of our knowledge, 
the only exception to the use of (±)-baclofen is constituted by a 
study reporting the suppressing effect of R(+)-baclofen on alco-
hol drinking in selectively bred, alcohol-preferring University 
of Chile bebedoras (UChB) rats, without testing, however, 
 S(−)-baclofen (31). Thus, the evidence of the enantioselective 
effect of baclofen on alcohol drinking (14, 15) is novel and 
interesting, as it might contribute toward explaining (a) the 
variability in magnitude of the reducing effect of (±)-baclofen 
on alcohol-related behaviors [from mild, though statistically 
significant, reductions, e.g., Ref. (23, 29), to virtually complete 
suppressions, e.g., Ref. (17, 20, 24, 28)] noticed among differ-
ent rodent studies and (b) the increase in alcohol drinking in 
rats reported in a relatively small number of studies (32–35). 
Variability in baclofen effect on alcohol consumption and 
craving has also been observed in clinical studies, both among 
different studies [reductions (36, 37); lack of effect (38, 39)] and 
within the same cohort of patients (40).
The present study was designed to contribute to this new 
line of research, testing the effect of the two baclofen enantiom-
ers on operant, oral alcohol self-administration in selectively 
bred Sardinian alcohol-preferring (sP) rats. Alcohol self- 
administration in sP rats has repeatedly been demonstrated to 
be sensitive to pharmacological manipulation of the GABAB 
receptor, by means of both orthosteric agonists, such as baclofen 
(24–26), and positive allosteric modulators (25, 26, 41–45). 
The study design included (a) a dose of (±)-baclofen (3 mg/kg) 
known to effectively reduce alcohol self-administration in sP rats 
(24–26), (b) doses of the more active enantiomer, R(+)-baclofen, 
calculated as corresponding to half of (0.75  mg/kg), equal to 
(1.5 mg/kg), and double (3 mg/kg) its content in the tested dose 
of (±)-baclofen, and (c) doses of the less active enantiomer, S(−)-
baclofen, calculated as corresponding to equal to (6  mg/kg), 
double (12 mg/kg), and fourfold (24 mg/kg) of its content in the 
tested dose of (±)-baclofen.
MaTerials anD MeThODs
All experimental procedures employed in the present study were 
conducted in accordance with the Italian law on the “Protection 
of animals used for scientific reasons.”
animals
Male sP rats (n = 96) from the 88th generation, and 60 days old at 
the start of the study, were utilized. Rats were alcohol-naive before 
the start of the study. Rats were housed three per cage in standard 
plastic cages with wood chip bedding. The animal facility was 
under an inverted 12:12-h light–dark cycle (lights on at 7:00 
p.m.), at a constant temperature of 22 ± 2°C and relative humid-
ity of approximately 60%. Over the 2-week period preceding the 
start of the study, rats were extensively habituated to handling 
and intraperitoneal injections; specifically, rats received 10 daily 
injections (Monday to Friday over both weeks) of 2 ml/kg saline. 
Food pellets (Harlan, San Pietro al Natisone, Italy) and water were 
always available in the home cage, except as noted.
apparatus
Self-administration sessions were conducted in modular cham-
bers (Med Associates, St. Albans, VT, USA) located in sound-
attenuated cubicles, with fans for ventilation and background 
white noise. The front panel of each chamber was equipped 
with (a) two retractable response levers, (b) one dual-cup liquid 
receptacle positioned between the two levers, and (c) two stimu-
lus lights (one green and one white) mounted above each lever. 
The liquid receptacle was connected by polyethylene tubes to 
two syringe pumps located outside the chamber. A white house 
light was centered at the top of the back wall of each chamber. 
For half of the rats, the right lever was associated with alcohol; 
achievement of the response requirement (RR) (a) activated 
the alcohol pump, resulting in the delivery of 0.1 ml of alcohol 
solution and (b) switched on the green light for the 2-s period 
of alcohol delivery; for these rats, the left lever was associated 
with water, and achievement of RR (a) activated the water pump, 
resulting in the delivery of 0.1 ml water and (b) switched on the 
white light for the 2-s period of water delivery. The study design 
was counterbalanced, so that the opposite condition was applied 
to the other half of the rats (left lever: alcohol; right lever: water).
experimental Procedure
Two-Bottle Choice Phase
Rats were initially exposed to the home cage two-bottle “alcohol 
vs. water” choice regimen with unlimited access for 24  h/day 
over 10 consecutive days. The alcohol solution was presented at a 
concentration of 10% (v/v). This initial phase was (a) part of the 
conventional procedure of alcohol self-administration employed 
in this laboratory with sP rats [e.g., Ref. (26)] and (b) conducted 
to allow the rats to become accustomed to the taste of alcohol 
and start to experience its pharmacological effects, in order to 
possibly shorten the subsequent auto-shaping phase once rats 
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were introduced into the operant chambers. During this phase, 
daily alcohol intake and preference (defined as the percent ratio 
between consumed volumes of alcohol solution and water) aver-
aged approximately 6.3 g/kg and 63%, respectively. On the last 
day, alcohol intake and preference averaged approximately 7.5 g/
kg and 77%, respectively.
Shaping, Training, and Maintenance Phases
Immediately after the two-bottle choice drinking period, rats 
were introduced into the operant chambers and trained to lever 
respond for alcohol. Self-administration sessions lasted 30 min 
(with the sole exception of the first session that lasted 120 min) 
and were conducted 5 days/week (Monday to Friday) during the 
first half of the dark phase of the daily light–dark cycle. Rats were 
deprived of water during the 12-h prior to the first session in the 
operant chamber. Rats were initially exposed to a fixed ratio 1 
(FR1) schedule of reinforcement for 10% alcohol (v/v) for four 
consecutive daily sessions. FR was then increased to FR2 and FR4 
over four consecutive sessions. In sessions 9 and 10, the alcohol 
solution was presented at a final concentration of 15% (v/v). Rats 
were then exposed to four consecutive sessions during which the 
water lever alone or the alcohol lever alone was available every 
other day; water and alcohol were available on FR1 and FR4, 
respectively. From then onward, both levers were concomitantly 
available (maintenance phase) for a total of 30 sessions conducted 
with FR4 and FR1 on the alcohol and water lever, respectively. 
In the last five sessions of the maintenance phase, the number 
of lever responses for alcohol averaged 243  ±  13, 245  ±  13, 
250 ± 12, 239 ± 15, and 248 ± 13 (mean ± SEM of n = 96 rats), 
respectively; estimated amount of self-administered alcohol 
averaged 0.94 ± 0.05, 0.94 ± 0.05, 0.99 ± 0.05, 0.92 ± 0.06, and 
0.94 ± 0.05 g/kg (mean ± SEM of n = 96 rats), respectively.
Test Phase
Rats were divided into eight groups of n  =  12 individuals, 
matched for body weight and number of lever responses on the 
alcohol lever over the last five consecutive sessions preceding the 
test session. Test session was conducted the day after termination 
of the 30-day maintenance phase. It was virtually identical to self-
administration sessions of the maintenance phase (i.e., RR on the 
alcohol and water lever was kept at FR4 and FR1, respectively; 
30-min duration). (±)-Baclofen (Sigma-Aldrich, Milan, Italy), 
R(+)-baclofen (Sigma-Aldrich, Milan, Italy), and S(−)-baclofen 
(Sigma-Aldrich, Milan, Italy) were dissolved in saline and admin-
istered intraperitoneally (injection volume: 2  ml/kg) 30  min 
before the start of the test session. (±)-Baclofen was administered 
at the dose of 3 mg/kg, according to the results of several, previ-
ous experiments demonstrating that it effectively suppressed 
alcohol self-administration in sP rats (24–26).  R(+)-baclofen was 
administered at the doses of 0.75, 1.5, and 3 mg/kg, correspond-
ing to half of, equal to, and double its content in the tested dose 
of (±)-baclofen [(±)-baclofen is indeed a 1:1 mixture of the two 
enantiomers]. S(−)-baclofen was administered at the doses of 6, 
12, and 24 mg/kg, corresponding to equal to, double, and fourfold 
of its content in the tested dose of (±)-baclofen. Vehicle condition 
was represented by administration of an equal volume of saline.
Variables and Data analysis
Variables were number of responses on each lever and estimated 
amount of self-administered alcohol (expressed in gram per 
kilogram of pure alcohol; determined from the number of earned 
reinforcers, as careful inspections at the end of each session indi-
cated that no alcohol was left in any receptacle). When normally 
distributed, data were analyzed by one-way ANOVA, followed 
by the Tukey’s test for post hoc comparisons; when not normally 
distributed, data were analyzed by Kruskal–Wallis test.
resUlTs
ANOVA indicated that drug treatment significantly affected 
both the number of lever responses for alcohol [F(7,88) = 8.79, 
P < 0.0001] and estimated amount of self-administered alcohol 
[F(7,88) = 7.24, P < 0.0001].
Treatment with 3 mg/kg (±)-baclofen produced a reduction 
of approximately 60%, in comparison to vehicle treatment, in 
number of lever responses for alcohol (P < 0.005, Tukey’s test) 
(Figure  1, top panel). Treatment with 0.75, 1.5, and 3  mg/kg 
R(+)-baclofen produced a dose-related reduction in number of 
lever responses for alcohol, reaching statistical significance at the 
doses of 1.5 (P < 0.05, Tukey’s test) and 3 (P < 0.0001, Tukey’s 
test) mg/kg, in correspondence of which the magnitude of the 
reducing effect – in comparison to vehicle treatment – averaged 
approximately 50 and 80%, respectively (Figure  1, top panel). 
Conversely, treatment with 6, 12, and 24  mg/kg S(−)-baclofen 
did not alter, in comparison to vehicle treatment, the number of 
lever responses for alcohol (Figure 1, top panel).
Similar changes, in comparison to vehicle treatment, were 
recorded in the estimated amount of self-administered alcohol 
(Figure 1, bottom panel): (a) treatment with 3 mg/kg (± )-baclofen 
produced a reduction of approximately 60% in comparison to 
vehicle treatment (P <  0.005, Tukey’s test), (b) treatment with 
1.5 (P < 0.05, Tukey’s test) and 3 (P < 0.0001, Tukey’s test) mg/
kg R(+)-baclofen produced a reduction of approximately 55 and 
80%, respectively, in comparison to vehicle treatment, and (c) 
treatment with 6, 12, and 24 mg/kg S(−)-baclofen was ineffective.
Kruskal–Wallis test indicated that drug treatment had no effect 
on number of lever responses for water [χ2 = 7.09, df = 7, P > 0.05]. 
The number of lever responses for water was negligible (averaging 
<2 per session at all treatment conditions) (data not shown).
DiscUssiOn
Treatment with 3 mg/kg (±)-baclofen produced a robust reduc-
tion in alcohol self-administration in alcohol-preferring sP rats: 
both the number of lever responses for alcohol and estimated 
amount of self-administered alcohol were indeed suppressed 
by treatment with 3 mg/kg (±)-baclofen. Additionally, analysis 
of cumulative response patterns indicated a markedly reduced 
frequency in lever responding for alcohol, over the entire first 
half of the self-administration session, in the rat group treated 
with 3 mg/kg (±)-baclofen in comparison to vehicle-treated rat 
group (Figure  2). These results closely replicate previous find-
ings obtained in sP rats exposed to experimental procedures of 
FigUre 1 | effect of treatment with racemic baclofen [(±)-baclofen], r(+)-baclofen, and s(−)-baclofen on number of lever responses for alcohol  
(top panel) and estimated amount of self-administered alcohol (bottom panel) in selectively bred sardinian alcohol-preferring (sP) rats. Rats were 
initially trained to lever respond for oral alcohol (15% v/v, in water) [fixed ratio 4 (FR4)] and water (FR1) in daily 30-min sessions. Test session was conducted under 
the above FR schedules of reinforcement. Each bar is the mean ± SEM of n = 12 rats. *P < 0.05, **P < 0.005, and ***P < 0.0001 in comparison to vehicle-treated 
rats (Tukey’s test).
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operant, oral alcohol self-administration identical to those used 
in the present study (24, 26). Notably, previous experiments 
demonstrated that acute treatment with 3 mg/kg (±)-baclofen did 
not affect, even minimally, spontaneous locomotor activity in sP 
rats (17, 18), suggesting that the suppressive effect on alcohol self-
administration observed in the present study was not due to any 
motor-impairing or sedative effect. Together, these data suggest 
that 3 mg/kg is a dose of (±)-baclofen suitable for functioning as 
reference when testing baclofen enantiomers in sP rats.
Racemic baclofen [(±)-baclofen] is composed of a 1:1 mixture 
of R- and S-configurations, with the R-enantiomer being 100–
1000 times more potent, both in vitro [e.g., Ref. (46)] and in vivo 
[e.g., Ref. (47, 48)], than the S-enantiomer. Therefore, R-baclofen 
is the enantiomer on which the pharmacological activity of (±)- 
baclofen is based. Accordingly, in the present study, R(+)-baclofen 
appeared to be twice as active as (±)-baclofen: administration 
of 1.5  mg/kg R(+)-baclofen reduced both the number of lever 
responses for alcohol and estimated amount of self-administered 
alcohol to an extent similar to that produced by administration 
of 3  mg/kg (±)-baclofen. Additionally, reductions produced 
by 0.75  mg/kg R(+)-baclofen [corresponding to 1.5  mg/kg 
(±)-baclofen] and 3  mg/kg R(+)-baclofen [corresponding to 
6  mg/kg (±)-baclofen] were proportionally smaller and larger, 
respectively, than that produced by 3 mg/kg (±)-baclofen.
Conversely, none of the three tested doses of S(−)-baclofen (6, 12, 
and 24 mg/kg) altered the number of lever responses for alcohol 
and estimated amount of self-administered alcohol, confirming its 
inactivity even at relatively high doses. A tendency toward a higher 
frequency of responding on the alcohol lever, in the rat group treated 
with 24 mg/kg S(−)-baclofen and during the 5–15 min time period 
of the self-administration session, was the only possible effect of 
S(−)-baclofen that could be detected (Figure 2).
FigUre 2 | effect of treatment with racemic baclofen [(±)-baclofen], r(+)-baclofen, and s(−)-baclofen on cumulative response pattern of  
self-administration for alcohol in selectively bred sardinian alcohol-preferring (sP) rats. Rats were initially trained to lever respond for oral alcohol  
(15% v/v, in water) [fixed ratio 4 (FR4)] and water (FR1) in daily 30-min sessions. Test session was conducted under the above schedules of reinforcement. Each 
point is the mean ± SEM of n = 12 rats.
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Together, data collected in the present study on R(+)-baclofen 
and S(−)-baclofen confirm the stereospecificity of baclofen 
observed in several receptor-binding [e.g., Ref. (46)] and behav-
ioral [e.g., Ref. (47)] studies. These data are also in agreement with 
the results of in vivo studies indicating that the R-enantiomer is 
around twice as active as (±)-baclofen [e.g., Ref. (47, 48)].
Apart from the temporarily limited increase in number of 
lever responses for alcohol induced by treatment with 24 mg/
kg S(−)-baclofen (Figure  2), the results of the present study 
are apparently far from replicating the recent findings of the 
capability of S(−)-baclofen to effectively stimulate alcohol 
intake in HAP mice and binge-like drinking in C57BL/6J 
mice (14, 15). Notably, stimulation and reduction of alcohol 
drinking by S(−)-baclofen and R(+)-baclofen, respectively, 
occurred at the same dose (10 mg/kg, i.p.), suggesting that the 
two enantiomers were equally potent in exerting their opposite 
effects (15). Conversely, in the present study, S(−)-baclofen was 
ineffective even at a dose (24 mg/kg) that was 16 times higher 
than the minimum effective dose of R(+)-baclofen (1.5  mg/
kg). A ceiling effect limiting S(−)-baclofen-induced increase 
in alcohol self-administration in sP rats does not seem to be 
a feasible explanation for the results of the present study, as 
several previous experiments have demonstrated that – under 
specific experimental conditions – sP rats can self-administer 
remarkably larger amounts of alcohol in even shorter self-
administration sessions [e.g., Ref. (43)]. Additionally, the 
number of lever responses for alcohol and estimated amount of 
self-administered alcohol in S(−)-baclofen-treated rat groups 
tend to be lower than those recorded over the final period of 
the self-administration phase preceding the pharmacological 
test with baclofen, suggesting that there was room for possible 
increases in both variables.
However, several methodological differences may 
explain these discrepancies. First, the two studies reporting 
 S(−)-baclofen-induced increase in alcohol drinking used 
mice (14,  15), whereas the present study used rats of a line 
selectively bred for high alcohol preference and consumption; 
species differences in the neural substrates mediating baclofen 
effects cannot be excluded. Second, the two studies reporting 
 S(−)-baclofen-induced increase in alcohol drinking employed 
two experimental procedures of alcohol drinking [namely, 
two-bottle “alcohol (10%, v/v) vs. water” choice regimen with 
unlimited access for 24  h/day; 2-h limited access to a single 
alcohol (20%, v/v) bottle during the dark phase of the light–dark 
cycle] (14, 15), whereas the present study employed an operant 
procedure of oral alcohol self-administration, in which rats 
were required to perform a given task (lever responding) to 
access alcohol; alcohol drinking and alcohol self-administration 
are likely differentiable for a number of aspects, including the 
underlying neural substrates and their sensitivity to phar-
macological manipulation. Experiments testing the effect of 
R(+)-baclofen and S(−)-baclofen in mice exposed to operant 
procedures of alcohol self-administration and/or rats exposed 
to alcohol drinking procedures might provide a contribution 
toward clarifying these discrepancies.
In conclusion, the results of the present study confirm sev-
eral previous findings indicating that (a) non-sedative doses of 
(±)-baclofen effectively suppressed the reinforcing properties 
of alcohol [e.g., Ref. (19–21, 23–27)] and (b) R-baclofen is the 
active enantiomer of baclofen [e.g., Ref. (46, 47)]. Conversely, 
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the results of the present study apparently do not extend to 
operant alcohol self-administration in sP rats the capabil-
ity of the supposedly inactive enantiomer, S(−)-baclofen, to 
stimulate alcohol drinking – including binge-like drinking – in 
mice (14,  15): treatment with even relatively high doses of 
S(−)-baclofen was indeed completely ineffective on alcohol 
self-administration in sP rats.
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